China approves Livzon Pharmaceutical’s COVID vaccine as booster

China has granted emergency use authorization to Livzon Pharmaceutical Group Inc. Covid-19 vaccine as a reminder, the company said on Friday, one of two new disease-fighting products the country has phased out in more than a year.

Livzon’s vaccine, based on the original coronavirus, if rolled out to the general public, would expand booster options for China’s 1.4 billion people, 90% of whom have been vaccinated and nearly 60% received a booster dose.

The United States has authorized updates of COVID-19 booster shots from Pfizer/BioNTech and Moderna that target the BA.4 and BA.5 Omicron subvariants, while countries including Canada and the UK have also ordered updated Omicron vaccine boosters for more campaigns. late this year.


Most people in China have received injections of inactivated vaccines from Sinovac or Sinopharm for primary vaccination, among seven domestically developed vaccines the country has approved for use between 2020 and 2021.

The data showed that other vaccines, ranging from injections of foreign mRNAs produced by Pfizer/BioNTech or Moderna to non-killed domestic candidates, elicited higher antibody readings against the Omicron variant as a mixed booster compared to to the use of a third dose of Sinovac or Sinopharm.

As China resumes lockdown due to COVID, the country has approved Livzon Pharmaceutical’s COVID-19 vaccine as a booster. Pictured: A healthcare worker tests people for COVID following an outbreak in Shenzen, China August 30, 2022. (REUTERS/David Kirton/Files/Reuters Photos)

Livzon’s protein-based vaccine, adopting a different technology from Sinovac and Sinopharm’s products, was one of two products Chinese officials said were recently cleared for use. The other has not been formally identified.

A booster dose of Livzon reduced the risk of symptomatic COVID-19 illness by 47.8% compared to those who just received two injections of inactivated vaccine, based on results of a trial with more than 10,000 participants and 110 cases, published in the medical journal Emerging Microbes & Infections.

The incremental booster efficacy against Omicron was 47.0%, compared to inactivated vaccine recipients, based on an analysis of 63 cases infected with the trial variant, according to the peer-reviewed article. peers.


Livzon is working on bivalent or multivalent vaccine candidates, which include designs targeting the BA.5 subvariant of OmicronYang Jiaming, deputy general manager of Livzon Mabpharm unit of Livzon, said at a health event in Beijing.

Sinopharm and Sinovac are conducting clinical trials for their specific Omicron candidates.

China currently allows only one booster dose after the primary vaccination. It has not yet approved doses manufactured abroad.